NEWS
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
2seventy bio and Bristol Myers Squibbhave decided to discontinue enrollment in the Phase 3 KarMMa-9 studyevaluating Abecma in newly diagnosed multiple myeloma patients. This decision is expected to result in over $80 million in cost savings for 2seventy bio and accelerate their path to breakeven in 2025.
The company reports positive momentum for Abecma, with expected third quarter U.S. revenue growth of approximately 30% from the second quarter revenue of $54 million. Demand, measured by new patients undergoing apheresis, is also expected to show double-digit growth compared to Q2 2024.
2seventy bio remains committed to expanding Abecma's reach to multiple myeloma patients, citing its differentiated safety profile and competitive efficacy, particularly when combined with effective bridging therapies.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2545Followers
107Following
28KVisitors
Follow